

# Pedro R Lowenstein

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6428110/publications.pdf>

Version: 2024-02-01

131  
papers

6,256  
citations

76196

40  
h-index

76769

74  
g-index

145  
all docs

145  
docs citations

145  
times ranked

8662  
citing authors

#	ARTICLE	IF	CITATIONS
1	Consensus guidelines for the detection of immunogenic cell death. <i>Oncolmmunology</i> , 2014, 3, e955691.	2.1	686
2	HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor Regression. <i>PLoS Medicine</i> , 2009, 6, e1000010.	3.9	310
3	Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. <i>Journal of Neuro-Oncology</i> , 2007, 85, 133-148.	1.4	300
4	ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma. <i>Science Translational Medicine</i> , 2016, 8, 328ra28.	5.8	212
5	Progress in gene therapy for neurological disorders. <i>Nature Reviews Neurology</i> , 2013, 9, 277-291.	4.9	202
6	Acute Direct Adenoviral Vector Cytotoxicity and Chronic, but Not Acute, Inflammatory Responses Correlate with Decreased Vector-Mediated Transgene Expression in the Brain. <i>Molecular Therapy</i> , 2001, 3, 36-46.	3.7	171
7	IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	169
8	Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination. <i>Nature Biotechnology</i> , 2001, 19, 582-585.	9.4	149
9	Immune Responses to Adenovirus and Adeno-Associated Vectors Used for Gene Therapy of Brain Diseases: The Role of Immunological Synapses in Understanding the Cell Biology of Neuroimmune Interactions. <i>Current Gene Therapy</i> , 2007, 7, 347-360.	0.9	144
10	Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy. <i>Nature Communications</i> , 2020, 11, 5687.	5.8	142
11	Stability of Lentiviral Vector-Mediated Transgene Expression in the Brain in the Presence of Systemic Antivector Immune Responses. <i>Human Gene Therapy</i> , 2005, 16, 741-751.	1.4	137
12	Mechanisms of Glioma Formation: Iterative Perivascular Glioma Growth and Invasion Leads to Tumor Progression, VEGF-Independent Vascularization, and Resistance to Antiangiogenic Therapy. <i>Neoplasia</i> , 2014, 16, 543-561.	2.3	131
13	Immunosuppressive Myeloid Cells™ Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy. <i>Molecular Therapy</i> , 2017, 25, 232-248.	3.7	130
14	Immunology of viral-vector-mediated gene transfer into the brain: an evolutionary and developmental perspective. <i>Trends in Immunology</i> , 2002, 23, 23-30.	2.9	125
15	Engineering patient-specific cancer immunotherapies. <i>Nature Biomedical Engineering</i> , 2019, 3, 768-782.	11.6	123
16	High-Density Lipoprotein-Mimicking Nanodiscs for Chemo-immunotherapy against Glioblastoma Multiforme. <i>ACS Nano</i> , 2019, 13, 1365-1384.	7.3	122
17	Combined Immunostimulation and Conditional Cytotoxic Gene Therapy Provide Long-term Survival in a Large Glioma Model. <i>Cancer Research</i> , 2005, 65, 7194-7204.	0.4	121
18	Treg Depletion Inhibits Efficacy of Cancer Immunotherapy: Implications for Clinical Trials. <i>PLoS ONE</i> , 2008, 3, e1983.	1.1	109

#	ARTICLE	IF	CITATIONS
19	Purine metabolism regulates DNA repair and therapy resistance in glioblastoma. <i>Nature Communications</i> , 2020, 11, 3811.	5.8	103
20	Strong Promoters Are the Key to Highly Efficient, Noninflammatory and Noncytotoxic Adenoviral-Mediated Transgene Delivery into the Brain in Vivo. <i>Molecular Therapy</i> , 2000, 2, 330-338.	3.7	102
21	Release of HMGB1 in Response to Proapoptotic Glioma Killing Strategies: Efficacy and Neurotoxicity. <i>Clinical Cancer Research</i> , 2009, 15, 4401-4414.	3.2	95
22	Fms-Like Tyrosine Kinase 3 Ligand Recruits Plasmacytoid Dendritic Cells to the Brain. <i>Journal of Immunology</i> , 2006, 176, 3566-3577.	0.4	88
23	Inflammatory and Anti-glioma Effects of an Adenovirus Expressing Human Soluble Fms-like Tyrosine Kinase 3 Ligand (hsFlt3L): Treatment with hsFlt3L Inhibits Intracranial Glioma Progression. <i>Molecular Therapy</i> , 2004, 10, 1071-1084.	3.7	86
24	One-year Expression From High-capacity Adenoviral Vectors in the Brains of Animals With Pre-existing Anti-adenoviral Immunity: Clinical Implications. <i>Molecular Therapy</i> , 2007, 15, 2154-2163.	3.7	78
25	CXCR4 increases <i>in-vivo</i> glioma perivascular invasion, and reduces radiation induced apoptosis: A genetic knockdown study. <i>Oncotarget</i> , 2016, 7, 83701-83719.	0.8	75
26	Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	70
27	Uncertainty in the Translation of Preclinical Experiments to Clinical Trials. <i>Why do Most Phase III Clinical Trials Fail?</i> . <i>Current Gene Therapy</i> , 2009, 9, 368-374.	0.9	70
28	Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model. <i>Neuro-Oncology</i> , 2008, 10, 19-31.	0.6	68
29	Antiglioma Immunological Memory in Response to Conditional Cytotoxic/Immune-Stimulatory Gene Therapy: Humoral and Cellular Immunity Lead to Tumor Regression. <i>Clinical Cancer Research</i> , 2009, 15, 6113-6127.	3.2	68
30	Natural Killer Cells Eradicate Galectin-1â€“Deficient Glioma in the Absence of Adaptive Immunity. <i>Cancer Research</i> , 2014, 74, 5079-5090.	0.4	62
31	Current state and future prospects of immunotherapy for glioma. <i>Immunotherapy</i> , 2018, 10, 317-339.	1.0	60
32	Characterizing and targeting <i>PDGFRA</i> alterations in pediatric high-grade glioma. <i>Oncotarget</i> , 2016, 7, 65696-65706.	0.8	55
33	Current Approaches for Glioma Gene Therapy and Virotherapy. <i>Frontiers in Molecular Neuroscience</i> , 2021, 14, 621831.	1.4	54
34	Gene therapy for brain tumors: Basic developments and clinical implementation. <i>Neuroscience Letters</i> , 2012, 527, 71-77.	1.0	53
35	G-CSF secreted by mutant IDH1 glioma stem cells abolishes myeloid cell immunosuppression and enhances the efficacy of immunotherapy. <i>Science Advances</i> , 2021, 7, eabh3243.	4.7	53
36	Blockade of mTOR Signaling via Rapamycin Combined with Immunotherapy Augments Antiglioma Cytotoxic and Memory T-Cell Functions. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 3024-3036.	1.9	48

#	ARTICLE	IF	CITATIONS
37	Synthetic High-density Lipoprotein Nanodiscs for Personalized Immunotherapy Against Gliomas. <i>Clinical Cancer Research</i> , 2020, 26, 4369-4380.	3.2	48
38	Glioblastoma Utilizes Fatty Acids and Ketone Bodies for Growth Allowing Progression during Ketogenic Diet Therapy. <i>IScience</i> , 2020, 23, 101453.	1.9	47
39	Plasmacytoid Dendritic Cells in the Tumor Microenvironment: Immune Targets for Glioma Therapeutics. <i>Neoplasia</i> , 2012, 14, 757-IN26.	2.3	46
40	Mutated Chromatin Regulatory Factors as Tumor Drivers in Cancer. <i>Cancer Research</i> , 2017, 77, 227-233.	0.4	46
41	Flt3L in Combination With HSV1-TK-mediated Gene Therapy Reverses Brain Tumor-induced Behavioral Deficits. <i>Molecular Therapy</i> , 2008, 16, 682-690.	3.7	43
42	Systemic Delivery of an Adjuvant CXCR4/CXCL12 Signaling Inhibitor Encapsulated in Synthetic Protein Nanoparticles for Glioma Immunotherapy. <i>ACS Nano</i> , 2022, 16, 8729-8750.	7.3	43
43	Combined Flt3L/TK Gene Therapy Induces Immunological Surveillance Which Mediates an Immune Response Against a Surrogate Brain Tumor Neoantigen. <i>Molecular Therapy</i> , 2011, 19, 1793-1801.	3.7	42
44	ATRX mutations and glioblastoma: Impaired DNA damage repair, alternative lengthening of telomeres, and genetic instability. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1167158.	0.3	41
45	Adenovirus-mediated expression of HSV1-TK or Fas ligand induces cell death in primary human glioma-derived cell cultures that are resistant to the chemotherapeutic agent CCNU. <i>Cancer Gene Therapy</i> , 2001, 8, 589-598.	2.2	40
46	Melanoma induced immunosuppression is mediated by hematopoietic dysregulation. <i>Oncolmmunology</i> , 2018, 7, e1408750.	2.1	38
47	A Novel Bicistronic High-Capacity Gutless Adenovirus Vector That Drives Constitutive Expression of Herpes Simplex Virus Type 1 Thymidine Kinase and Tet-Inducible Expression of Flt3L for Glioma Therapeutics. <i>Journal of Virology</i> , 2010, 84, 6007-6017.	1.5	37
48	Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy. <i>Clinical Immunology</i> , 2018, 189, 34-42.	1.4	37
49	Engineering the Brain Tumor Microenvironment Enhances the Efficacy of Dendritic Cell Vaccination: Implications for Clinical Trial Design. <i>Clinical Cancer Research</i> , 2011, 17, 4705-4718.	3.2	35
50	Fyn tyrosine kinase, a downstream target of receptor tyrosine kinases, modulates antiglioma immune responses. <i>Neuro-Oncology</i> , 2020, 22, 806-818.	0.6	34
51	Gene Therapy-Mediated Reprogramming Tumor Infiltrating T Cells Using IL-2 and Inhibiting NF- $\kappa$ B Signaling Improves the Efficacy of Immunotherapy in a Brain Cancer Model. <i>Neurotherapeutics</i> , 2012, 9, 827-843.	2.1	33
52	Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma. <i>Journal of Visualized Experiments</i> , 2015, , .	0.2	33
53	Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments. <i>Frontiers in Pharmacology</i> , 2021, 12, 680021.	1.6	33
54	Preclinical Characterization of Signal Transducer and Activator of Transcription 3 Small Molecule Inhibitors for Primary and Metastatic Brain Cancer Therapy. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 349, 458-469.	1.3	32

#	ARTICLE	IF	CITATIONS
55	Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models. <i>Clinical Cancer Research</i> , 2014, 20, 1555-1565.	3.2	32
56	ATRX loss in glioma results in dysregulation of cell-cycle phase transition and ATM inhibitor radio-sensitization. <i>Cell Reports</i> , 2022, 38, 110216.	2.9	32
57	Immunological thresholds in neurological gene therapy: highly efficient elimination of transduced cells might be related to the specific formation of immunological synapses between T cells and virus-infected brain cells. <i>Neuron Glia Biology</i> , 2006, 2, 309-322.	2.0	29
58	Gene Transfer into Rat Brain Using Adenoviral Vectors. <i>Current Protocols in Neuroscience</i> , 2010, 50, Unit 4.24.	2.6	29
59	Spatiotemporal analysis of glioma heterogeneity reveals COL1A1 as an actionable target to disrupt tumor progression. <i>Nature Communications</i> , 2022, 13, .	5.8	29
60	Natural killer cells require monocytic Gr-1 <sup>+</sup> /CD11b <sup>+</sup> myeloid cells to eradicate orthotopically engrafted glioma cells. <i>Oncoimmunology</i> , 2016, 5, e1163461.	2.1	28
61	Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients. <i>Clinical Immunology</i> , 2018, 189, 43-51.	1.4	27
62	Uncovering Spatiotemporal Heterogeneity of High-Grade Gliomas: From Disease Biology to Therapeutic Implications. <i>Frontiers in Oncology</i> , 2021, 11, 703764.	1.3	27
63	Blocking Immunosuppressive Checkpoints for Glioma Therapy: The More the Merrier!. <i>Clinical Cancer Research</i> , 2014, 20, 5147-5149.	3.2	24
64	The Case for Immunosuppression in Clinical Gene Transfer. <i>Molecular Therapy</i> , 2005, 12, 185-186.	3.7	22
65	Progress and challenges in viral vector-mediated gene transfer to the brain. <i>Current Opinion in Molecular Therapeutics</i> , 2002, 4, 359-71.	2.8	22
66	Input Virion Proteins: Cryptic Targets of Antivector Immune Responses in Preimmunized Subjects. <i>Molecular Therapy</i> , 2004, 9, 771-774.	3.7	21
67	Safety Profile of Gutless Adenovirus Vectors Delivered into the Normal Brain Parenchyma: Implications for a Glioma Phase 1 Clinical Trial. <i>Human Gene Therapy Methods</i> , 2012, 23, 271-284.	2.1	21
68	Matrix Metalloproteinase Activity in Infections by an Encephalitic Virus, Mouse Adenovirus Type 1. <i>Journal of Virology</i> , 2017, 91, .	1.5	21
69	Self-organization in brain tumors: How cell morphology and cell density influence glioma pattern formation. <i>PLoS Computational Biology</i> , 2020, 16, e1007611.	1.5	21
70	Immunology of Neurological Gene Therapy: How T Cells Modulate Viral Vector-Mediated Therapeutic Transgene Expression Through Immunological Synapses. <i>Neurotherapeutics</i> , 2007, 4, 715-724.	2.1	20
71	Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathology. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 14443-14448.	3.3	20
72	Therapeutic Efficacy of Immune Stimulatory Thymidine Kinase and fms-like Tyrosine Kinase 3 Ligand (TK/Flt3L) Gene Therapy in a Mouse Model of High-Grade Brainstem Glioma. <i>Clinical Cancer Research</i> , 2020, 26, 4080-4092.	3.2	18

#	ARTICLE	IF	CITATIONS
73	Immune-mediated Loss of Transgene Expression From Virally Transduced Brain Cells Is Irreversible, Mediated by IFN $\gamma$ , Perforin, and TNF $\alpha$ , and due to the Elimination of Transduced Cells. <i>Molecular Therapy</i> , 2012, 20, 808-819.	3.7	17
74	Single vs. combination immunotherapeutic strategies for glioma. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 543-554.	1.4	17
75	Hemispherical Pediatric High-Grade Glioma: Molecular Basis and Therapeutic Opportunities. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9654.	1.8	16
76	Prospects of biological and synthetic pharmacotherapies for glioblastoma. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 305-317.	1.4	16
77	Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 659-684.	1.9	15
78	Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells. <i>Journal of Visualized Experiments</i> , 2015, , .	0.2	14
79	Epigenetic reprogramming and chromatin accessibility in pediatric diffuse intrinsic pontine gliomas: a neural developmental disease. <i>Neuro-Oncology</i> , 2020, 22, 195-206.	0.6	14
80	A novel miR1983-TLR7-IFN $\gamma$ circuit licenses NK cells to kill glioma cells, and is under the control of galectin-1. <i>Oncolmmunology</i> , 2021, 10, 1939601.	2.1	14
81	Tumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa042.	0.4	12
82	Long-Term Transgene Expression within the Anterior Pituitary Gland in Situ: Impact on Circulating Hormone Levels, Cellular and Antibody-Mediated Immune Responses*Supported by grants from the BBSRC (UK), The Wellcome trust (UK), The Royal Society, and European Union-Biomed grants, contract no. BMH4-CT98â€“3277, BMH4-CT98â€“0297 (to P.R.L. and M.G.C.), , 0, .		12
83	Assessing the Role of STAT3 in DC Differentiation and Autologous DC Immunotherapy in Mouse Models of GBM. <i>PLoS ONE</i> , 2014, 9, e96318.	1.1	12
84	Reversibility of glioma stem cellsâ€™ phenotypes explains their complex <i>in vitro</i> and <i>in vivo</i> behavior: Discovery of a novel neurosphere-specific enzyme, cGMP-dependent protein kinase 1, using the genomic landscape of human glioma stem cells as a discovery tool. <i>Oncotarget</i> , 2016, 7, 63020-63041.	0.8	12
85	Dendritic cells and immune responses in the central nervous system. <i>Trends in Immunology</i> , 2002, 23, 70.	2.9	10
86	Lentiviral-Induced High-Grade Gliomas in Rats: The Effects of PDGFB, HRAS-G12V, AKT, and IDH1-R132H. <i>Neurotherapeutics</i> , 2014, 11, 623-635.	2.1	10
87	Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies. <i>Frontiers in Oncology</i> , 2021, 11, 631037.	1.3	10
88	Rodent Glioma Models: Intracranial Stereotactic Allografts and Xenografts. <i>Neuromethods</i> , 2012, 77, 229-243.	0.2	9
89	Virus Vectors for use in the Central Nervous System. <i>International Review of Neurobiology</i> , 2003, 55, 3-64.	0.9	8
90	Cracking the glioma-NK inhibitory code: toward successful innate immunotherapy. <i>Oncolmmunology</i> , 2014, 3, e965573.	2.1	8

#	ARTICLE	IF	CITATIONS
91	Gene Therapy for the Treatment of Neurological Disorders: Central Nervous System Neoplasms. <i>Methods in Molecular Biology</i> , 2016, 1382, 467-482.	0.4	8
92	Molecular ablation of tumor blood vessels inhibits therapeutic effects of radiation and bevacizumab. <i>Neuro-Oncology</i> , 2018, 20, 1356-1367.	0.6	8
93	Targeting gliomas with STAT3-silencing nanoparticles. <i>Molecular and Cellular Oncology</i> , 2021, 8, 1870647.	0.3	8
94	Laser Capture Microdissection of Glioma Subregions for Spatial and Molecular Characterization of Intratumoral Heterogeneity, Oncostreams, and Invasion. <i>Journal of Visualized Experiments</i> , 2020, , .	0.2	7
95	Immune-stimulatory (TK/Flt3L) gene therapy opens the door to a promising new treatment strategy against brainstem gliomas. <i>Oncotarget</i> , 2020, 11, 4607-4612.	0.8	7
96	With a Little Help From My f(X)riends!: The Basis of Ad5-Mediated Transduction of the Liver Revealed. <i>Molecular Therapy</i> , 2008, 16, 1004-1006.	3.7	6
97	An Optimized Protocol for In Vivo Analysis of Tumor Cell Division in a Sleeping Beauty-Mediated Mouse Glioma Model. <i>STAR Protocols</i> , 2020, 1, 100044.	0.5	6
98	The Value of EGFRvIII as the Target for Glioma Vaccines. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , 42-50.	1.8	5
99	Native Chromatin Immunoprecipitation Using Murine Brain Tumor Neurospheres. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	4
100	3131 ONCOSTREAMS: NOVEL DYNAMICS PATHOLOGICAL MULTICELLULAR STRUCTURES INVOLVED IN GLIOBLATOMA GROWTH AND INVASION. <i>Journal of Clinical and Translational Science</i> , 2019, 3, 111-111.	0.3	4
101	Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	4
102	ATIM-44. A PHASE I FIRST-IN-HUMAN TRIAL OF TWO ADENOVIRAL VECTORS EXPRESSING HSV1-TK AND FLT3L FOR TREATING NEWLY DIAGNOSED RESECTABLE MALIGNANT GLIOMA: THERAPEUTIC REPROGRAMMING OF THE BRAIN IMMUNE SYSTEM. <i>Neuro-Oncology</i> , 2019, 21, vi11-vi11.	0.6	4
103	Genetically Engineered Mouse Model of Brainstem High-Grade Glioma. <i>STAR Protocols</i> , 2020, 1, 100165.	0.5	4
104	Identification and Visualization of CD8+ T Cell Mediated IFN- $\gamma$ Signaling in Target Cells during an Antiviral Immune Response in the Brain. <i>PLoS ONE</i> , 2011, 6, e23523.	1.1	4
105	Challenges in the evaluation, consent, ethics and history of early clinical trials - Implications of the Tuskegee 'trial' for safer and more ethical clinical trials. <i>Current Opinion in Molecular Therapeutics</i> , 2009, 11, 481-4.	2.8	4
106	Multiple Expressed Endogenous Glioma Epitopes as Novel Vaccines for Gliomas. <i>Clinical Cancer Research</i> , 2016, 22, 4760-4762.	3.2	3
107	Functional characterization of tumor antigen-specific T-cells isolated from the tumor microenvironment of sleeping beauty induced murine glioma models. <i>Methods in Enzymology</i> , 2020, 631, 91-106.	0.4	2
108	CSIG-08. DYNAMICS OF GLIOMA GROWTH: SELF-ORGANIZATION GUIDES THE PATTERNING OF THE EXTRACELLULAR MATRIX AND REGULATES TUMOR PROGRESSION. <i>Neuro-Oncology</i> , 2018, 20, vi44-vi44.	0.6	1

#	ARTICLE	IF	CITATIONS
109	TMIC-62. FYN, AN EFFECTOR OF ONCOGENIC RECEPTOR TYROSINE KINASES SIGNALING IN GLIOBLASTOMA, INHIBITS ANTI-GLIOMA IMMUNE RESPONSES: IMPLICATIONS FOR IMMUNOTHERAPY. <i>Neuro-Oncology</i> , 2019, 21, vi261-vi261.	0.6	1
110	HMGB1 Mediates Endogenous TLR2 Activation And Brain Tumor Regression.. <i>FASEB Journal</i> , 2008, 22, 515-515.	0.2	1
111	Murine brain tumor microenvironment immunophenotyping using mass cytometry. <i>STAR Protocols</i> , 2022, 3, 101357.	0.5	1
112	Viral gene therapy for central nervous system diseases. , 2008, , 424-434.		0
113	Glioma trials and viral tribulations: can anything be concluded from non-controlled trials?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 125-125.	0.9	0
114	ANGI-10. GENETIC DOWN REGULATION OF CXCR4 IN GLIOMA CELLS REDUCES INVASION, REDUCES TUMOR PROGRESSION, AND INCREASES SENSITIVITY TO RADIATION. <i>Neuro-Oncology</i> , 2016, 18, vi17-vi17.	0.6	0
115	CBIO-10. REVERSIBILITY OF GLIOMA STEM CELLSâ€™ SPHERE FORMATION EXPLAINS THEIR IN VITRO BEHAVIOR AND IN VIVO TUMORIGENESIS POTENTIAL. <i>Neuro-Oncology</i> , 2016, 18, vi37-vi37.	0.6	0
116	IMMU-58. IDH1 MUTATION REGULATES MYELOID CELLS MEDIATED IMMUNOSUPPRESSION IN GLIOMA. <i>Neuro-Oncology</i> , 2017, 19, vi125-vi126.	0.6	0
117	IMMU-63. IDH1 MUTATION REGULATE MYELOID CELLS PLASTICITY MEDIATING ANTI-GLIOMA IMMUNOTHERAPY. <i>Neuro-Oncology</i> , 2018, 20, vi135-vi136.	0.6	0
118	HGG-08. ATRX LOSS IN PEDIATRIC GBM RESULTS IN EPIGENETIC DYSREGULATION OF G2/M CHECKPOINT MAINTENANCE AND SENSITIVITY TO ATM INHIBITION. <i>Neuro-Oncology</i> , 2019, 21, ii88-ii88.	0.6	0
119	EXTH-47. THERAPEUTIC REVERSAL OF PRENATAL PONTINE ID1 SIGNALING IN DIPG. <i>Neuro-Oncology</i> , 2019, 21, vi92-vi92.	0.6	0
120	TMIC-58. THE CELLULAR AND MOLECULAR BASIS FOR MESENCHYMAL TRANSFORMATION IN GLIOMAS. <i>Neuro-Oncology</i> , 2019, 21, vi260-vi260.	0.6	0
121	TMIC-35. IDH1 MUTATION IN GLIOMA REPROGRAMS EARLY MYELOID DIFFERENTIATION IN THE BONE MARROW (BM) TO PRODUCE NON-IMUNESUPPRESSIVE NEUTROPHILS. <i>Neuro-Oncology</i> , 2019, 21, vi255-vi255.	0.6	0
122	Depletion of CD25+ T cells inhibits CD8+ T cells clonal expansion and glioblastoma multiforme regression.. <i>FASEB Journal</i> , 2008, 22, 514-514.	0.2	0
123	Therapeutic implications of perivascular invasion in the context of high-density brain microvascular networks: A study on recursive pattern formation in malignant glioma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2057-2057.	0.8	0
124	Gene Therapy Approaches Using Reproducible and Fully Penetrant Lentivirus-Mediated Endogenous Glioma Models. <i>Neuromethods</i> , 2015, , 341-354.	0.2	0
125	CBIO-03. ATRX LOSS IN GLIOMA RESULTS IN EPIGENETIC DYSREGULATION OF CELL CYCLE PHASE TRANSITION. <i>Neuro-Oncology</i> , 2020, 22, ii16-ii16.	0.6	0
126	Title is missing!. , 2020, 16, e1007611.		0



#	ARTICLE	IF	CITATIONS
127	Title is missing!. , 2020, 16, e1007611.		0
128	Title is missing!. , 2020, 16, e1007611.		0
129	Title is missing!. , 2020, 16, e1007611.		0
130	The Brain as a Target for Gene Therapy. , 0, , 153-165.		0
131	Immune Responses to Viral Vectors Injected Systemically or into the CNS. , 0, , 167-179.		0